Home

Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)

4.7200
+0.0900 (1.94%)
NASDAQ · Last Trade: Sep 28th, 2:48 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
10 Hidden-Gem AI Stocks to Buy Right Nowfool.com
From AI-powered insurance bots to drug discovery platforms, these overlooked stocks offer pure-play exposure to artificial intelligence without trillion-dollar valuations.
Via The Motley Fool · September 27, 2025
Cramer's Friday Watchlist: AI Soars as Consumer Stumbles Amidst Economic Divide
As the trading week draws to a close on Friday, September 26, 2025, Jim Cramer, the influential host of CNBC's "Mad Money," has once again offered his discerning insights into the stock market's immediate landscape. His top ten things to watch highlight a stark and growing bifurcation in the U.
Via MarketMinute · September 26, 2025
Jim Cramer Says This Financial Stock Is A 'Total Spec,' Likes Dutch Bros,benzinga.com
On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and then buying some of the stock in the $40s.
Via Benzinga · September 26, 2025
Earnings Scheduled For August 5, 2025benzinga.com
Via Benzinga · August 5, 2025
Recursion Pharmaceuticals Earnings Previewbenzinga.com
Via Benzinga · August 4, 2025
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Nowfool.com
BigBear.ai is bigger than both of these AI-focused companies now. That could change.
Via The Motley Fool · September 26, 2025
The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of
Via MarketMinute · September 19, 2025
Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape
Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery for biotechnology companies. This strategic move aims to level the playing field, granting smaller biotechs access to sophisticated AI models trained on decades
Via MarketMinute · September 19, 2025
Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch.fool.com
Most of Nvidia's AI bets are riding on one stock.
Via The Motley Fool · September 15, 2025
What Analysts Are Saying About Recursion Pharmaceuticals Stockbenzinga.com
Via Benzinga · September 11, 2025
When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sortsfool.com
Nvidia's six-stock portfolio of publicly traded AI stocks was worth $4.3 billion at the end of the second quarter, and the company also owns stakes in many privately held AI start-ups.
Via The Motley Fool · September 3, 2025
3 AI Stocks Disrupting Trillion-Dollar Industriesfool.com
These three companies are using artificial intelligence (AI) to transform defense, pharmaceuticals, and banking.
Via The Motley Fool · September 2, 2025
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Todayfool.com
This AI company isn't yet living up to the hype.
Via The Motley Fool · August 29, 2025
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and
Via MarketMinute · August 27, 2025
1 Reason to Buy This Beaten-Down Artificial Intelligence (AI) Stock, and 2 Reasons to Sellfool.com
There might be better artificial intelligence (AI) stocks out there to buy.
Via The Motley Fool · August 25, 2025
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explodefool.com
The artificial intelligence revolution is leaving no opportunity unaddressed.
Via The Motley Fool · August 23, 2025
Why Recursion Pharmaceuticals Stock Caught a Cold This Weekfool.com
The few news items from and about the company weren't all that positive.
Via The Motley Fool · August 22, 2025
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Termfool.com
These companies are in the right place at the right time with the right products.
Via The Motley Fool · August 10, 2025
Why Recursion Pharmaceuticals Stock Tanked on Tuesdayfool.com
It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.
Via The Motley Fool · August 5, 2025
Recursion (RXRX) Q2 Revenue Jumps 33%fool.com
Via The Motley Fool · August 5, 2025
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimatesbenzinga.com
Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per share, missing estimates for a loss of 34 cents per share.
Via Benzinga · August 5, 2025
Recursion Pharmaceuticals-A (NASDAQ:RXRX) Reports Mixed Q2 2025 Earnings: Revenue Beat but EPS Misschartmill.com
Recursion Pharmaceuticals (RXRX) reported mixed Q2 2025 results, beating revenue estimates with $19.22M but missing EPS at -$0.41. Shares rose 5.5% pre-market amid clinical progress and Sanofi partnership milestones.
Via Chartmill · August 5, 2025
The Dawn of Hyper-Personalization: How Generative AI is Reshaping Our Digital World
The digital landscape is undergoing a profound transformation as personalized AI, particularly generative AI models, are increasingly being fine-tuned to individual preferences and histories. This shift moves beyond generic interactions, creating highly tailored and dynamic digital environments that promise to revolutionize user experience across entertainment, e-commerce, and healthcare. The immediate
Via MarketMinute · August 4, 2025
2 Beaten-Down Stocks With Incredible Upside Potentialfool.com
Getting in on the ground floor with these companies might lead to superior returns.
Via The Motley Fool · August 3, 2025
Why Recursion Pharmaceuticals Stock Got Mashed on Mondayfool.com
Investors weren't cheered by news from one of the biotech's rivals.
Via The Motley Fool · July 28, 2025